In a large immunotherapy cohort of BLCA (IMvigor210), we found that S100A5 expression was highest in the desert immune phenotype, TC0 (lowest PD‐L1 expression on tumor cells), and IC0 (lowest PD‐L1 expression on immune cells) (Figure 6H–J). This evidence concerns the gene S100A5 and bladder transitional cell carcinoma.